case study on uterine cancer

We report a case of a 31-year-old patient with an endometrial cancer diagnosed at stage II according to the International Federation of Gynecology and Obstetrics (FIGO), 2000 classification of endometrial cancer (8). This case study will provide a useful guide in diagnosis of EC for the sonographer.

Maria Lozano was already well into menopause when she started experiencing the most common symptom of endometrial cancer (also known as uterine cancer): abnormal vaginal bleeding. "After 10 years of not having my period, suddenly I was bleeding again," says Maria, who was 59 at the time of her stage III endometrial cancer diagnosis.. "My sister told me I needed to see a doctor."

Although most cases of EC occur after menopause, it has been reported in women of reproductive age, with 4% of cases occurring in women aged 40 years or younger (Lee et al., 2007). Here, we report an extremely rare case of a juvenile woman with EC, despite having no risk factors such as obesity or family history.

Introduction. Uterine carcinosarcomas are rare tumors comprising less than 5% of uterine malignancies [1, 2]. Uterine carcinosarcomas are extremely aggressive undifferentiated carcinomas which include both carcinomatous and sarcomatous elements, arising from a single malignant epithelial clone [2 - 6]. The prognosis is often poor, with 30 ...

Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005;97:375-384. Crossref. PubMed. Google Scholar. 14.

Endometrial carcinoma is the most common type of gynecological cancer whose incidence is increasing. Reports indicate that about 40 100 new cases were diagnosed in 2008, and 52 630 new cases were diagnosed in 2014 in the United States. 1-3 This malignant disease affects approximately 1 in every 50 women, with most of the cases presenting in postmenopausal women. 1 Endometrial carcinoma has ...

EP: 8. Endometrial Carcinoma: Clinical Case Scenario 3. EP: 9. Sequencing Therapy for MSI-High and MMR-Proficient Endometrial Carcinomas. David O'Malley, MD: Let's go to our third case. This ...

Case Studies Endometrial carcinoma is the most common type of gynecological cancer whose incidence is increasing. Reports indicate that about 40100 new cases were diag - nosed in 2008, and 52630 new cases were diagnosed in 2014 in the United States.1-3 This malignant disease affects approximately 1 in every 50 women, with most of

In this study, we report two cases of DEC with different presentation. Case 2 presented with the invasion to the bladder, rectum, and LN metastases. In contrast, the tumor in case 1 advanced into the endometrial cavity, similar to an endometrial polyp, without myometrial invasion. Hence, the diagnosis was established early.

breast cancer in this single institution study. However, an associ-ation between tamoxifen use and a specific uterine histology was not observed and the study was likely underpowered to answer this question. Another single institution study evaluated women with endometrial cancer and found 8% had a history of breast cancer,

Advanced Endometrial Carcinoma: Treatment Pipeline. Robert L. Coleman, MD, FACOG, FACS: This is a 64-year-old postmenopausal woman who presented with abnormal uterine bleeding for about 2 months. She has 2 grown children, underwent menopause at age 57, and has no known family history of cancer. Her past medical history is significant for a body ...

Treatment Options for Advanced Stage Relapsed Endometrial Carcinoma. EP: 4. Dose Reduction in Endometrial Carcinoma Treatment. EP: 5. Endometrial Carcinoma: Clinical Case Scenario 2. EP: 6. I/O ...

Non-endometrioid tumors (including serous, clear cell, carcinosarcoma, and other, rarer types of endometrial cancer) are often more aggressive and have a poor prognosis. This page highlights some of the latest research in endometrial cancer, NCI-supported programs that are fueling progress, and research findings from recent studies.

In this case, the transverse maximum diameter of the primary tumor was 10.5 cm with bilateral parametrial infiltration, and in recent study, disease-free survival rate of the patients who have stage IIIB cervical cancer more than 8 cm was 16.7%. Another previous study revealed that hypoxia may contribute to lower local control of bulky tumor.

The study population of cases consisted of all patients with primary cancer of the uterine body admitted to six of the 23 hospitals in the Greater Baltimore area during the period January 1, 1973 ...

Uterine cancer accounts for about 3% of all new cancer cases but is the most common cancer of the female reproductive system, with 65,950 estimated new cases in 2022. Studies show that incidence rates of uterine cancer have been rising in the United States, particularly among Black women.

Endometrial cancer concerns about 3% of premenopausal women. We present a case of a 25-year-old patient who underwent endometrial curettage because of irregular menstrual bleeding for the last 5 months. Histopathology revealed endometrial cancer. We attempted to apply a conservative treatment. During the next 6 months the patient was treated ...

Abstract. Endometrial adenocarcinoma (ADK) is one of the most common uterine cancer and the fourth neoplasia mortality cause in women according to the literature data. ADK is encountered in the sixth decade of life, the mean age being 63 years. Only 2-5% of cases are found in women less than 40 years old.

Concerns about hair products and cancer. Data from the Sister Study has been used in the past to look for possible links between hair products and other cancers, especially cancers that grow in response to hormones. This includes breast and ovarian cancer, as well as uterine cancer.

Among them, synchronous endometrial and ovarian cancers (SEOCs) are the most common types of malignancy and account for 50%-70% of all synchronous female genital tract tumors with a frequency of 5% among endometrial and 10% among ovarian primary tumors. [ 2] SEOCs are defined as the simultaneous presence of these two cancers at the time of ...

Endometrial cancer (EC) is one of the most prevalent gynecological malignancies [].Immunotherapy, particularly immune checkpoint inhibitors, has made significant advances in the treatment of EC [2, 3].The incidence of EC is on the rise with the increasing rate of obesity [].Studies have discovered a positive correlation between the cholesterol intake and the risk of EC [5, 6].

Lenvatinib (Lenvima) plus pembrolizumab (Keytruda) compared with carboplatin plus paclitaxel, achieved substantial antitumor activity in patients with stage III/IV recurrent endometrial carcinoma, according to findings from an exploratory analysis of the phase 3 ENGOT-en9/LEAP-001 study (NCT03884101) presented at the 2024 European Society for Medical Oncology (ESMO) Congress.

SMARCA4-deficient tumors have been reported in various organs and are associated with a poor prognosis. SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) was first described in 2018. Conversely, loss of SMARCA4 (BRG1) expression, as observed by immunostaining, has been observed in several cases of undifferentiated endometrial carcinoma. SDUS has considerable morphologic overlap with ...

TROPION-PanTumor03 Study Background. The global, open-label, phase 2 TROPION-PanTumor03 study is exploring Dato-DXd as a single-agent and in combination regimens with various anticancer treatments across multiple tumor types. The results presented at ESMO were from the study arms focused on ovarian cancer and endometrial cancer.

Although it makes up only about 2% of endometrial cancers, the 100% mortality rate means finding a treatment is crucial. "With a lot of cancer we study, we plot the median survival in years," says ...

Background: The majority of women with endometrial cancer (EC) present at an early stage with an associated 5-year survival rate of >90%. High rates of early detection are attributed to warning symptoms; however, the prevalence of such symptoms has not been well defined. Methods: A case-control study was conducted assessing the prevalence of ...

This study aimed to comprehensively evaluate the bidirectional causal effects between breast cancer (BC) and a range of uterine diseases (UDs), including endometriosis, endometrial cancer (EC), uterine leiomyoma (UL), uterine polyps (UP), and cervical cancer (CC). Hence, a 2SMR analysis was employed.

However, when ovarian cancer coexists with preexisting endometriosis, there can be noticeable variations in CA-125 levels. 13 This is because the growth rates of cancerous cells differ from those of endometrial cells. The lack of substantial variations in CA-125 levels between ovarian endometriosis and EAOC in our study may be attributed to the ...

Ensure that all surgical and nursing staff are well-trained in the efficient use of ICG to minimize wastage. Considerations for Disease Sites. Until the shortage is lifted, ICG use should be reserved for presumed early stage endometrial cancer, unifocal vulvar cancers with a tumor size <4 centimeters (cm) and a negative clinical groin exam, and cervical cancers with a tumor size ≤2 cm.

Methods. This study retrospectively included 212 non-EEC patients, with histological types including serous carcinoma (SC), clear cell carcinoma (CCC), mixed carcinoma (MC), undifferentiated carcinoma (UC), and carcinosarcoma (CS). p53 IHC was interpreted as normal/wild-type and abnormal/mutant-type, the latter including overexpression, complete absence, and cytoplasmic staining patterns.